ABL-501

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameABL-501

Drug Alias NameABL-501

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsLymphocyte activation gene 3 protein inhibitorsT lymphocytes stimulants +[4]

TargetsProgrammed death-ligand 1Lymphocyte activation gene 3 protein

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAbl Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A